USA Digital Health: Navigating FDA's New Cybersecurity Chaos with Pure Global

Last week, the US FDA's new digital health pilot program sent ripples through the MedTech industry. This is more than a simple regulatory update; it's a pivotal shift that moves cybersecurity from a compliance task to a major commercial and contractual battleground, fundamentally changing the rules for market access. This episode breaks down how the convergence of new FDA initiatives and proactive industry standards is creating unforeseen hurdles. The burden of proof for cybersecurity has escalated, now extending beyond the device to the entire healthcare network's integrity, placing immense pressure on manufacturers during commercial negotiations. **Case In Point:** A scale-up with a groundbreaking AI diagnostic tool cleared initial FDA cybersecurity hurdles, only to face a new sales-blocking wall. Hospitals are now demanding they sign contracts with complex new liability clauses based on the latest industry guidance. This unexpected commercial barrier is delaying market entry and draining resources. How can they succeed when the goalposts have shifted from regulatory approval to contractual warfare? **Key Questions This Week:** * What is the FDA's new digital health pilot really about? * Why is new cybersecurity contract language suddenly a major sales blocker? * How has the burden of proof for security shifted from the device to the entire hospital network? * What does a "secure product development framework" mean in practice for your team? * Are your current regulatory documents strong enough for these new commercial negotiations? * Beyond compliance, how do you manage cybersecurity as a continuous business risk? For more information, contact us at [email protected], visit https://pureglobal.com/, or access our FREE AI tools and medical device database at https://pureglobal.ai/.